Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

Impact · against what's priced in

AnaptysBio is pivoting to a lean, royalty-focused operating model with a $100 million share buyback and the spin-off of First Tracks Biotherapeutics. This strategic shift toward capital return and reduced overhead provides a concrete valuation floor and a clear path for returning value to shareholders.

ANAB+0.70

No priced-in read yet